Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
–Well tolerated; dose dependent biological effects consistent with CD40-mediated immune cell activity––Program development expanded based on results observed to date– […]